SMO Molekülinformation
Molecule Name
Smoothened receptor
Molekülalias
SMO,smoothened, frizzled class receptor,CRJS, FZD11, Gx, PHLS, SMOH
Drug Development Progress
Anzahl der klinischen Arzneimittel5
Anzahl der inverkehr gebrachten Arzneimittel3
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
SMO，SMOH，Smoothened， Frizzled Class Receptor，Smoothened， Frizzled Family Receptor，Frizzled Family Member 11，Protein Gx，Seven Transmembrane Helix Receptor，Smoothened Homolog (Drosophila)，Smoothened Homolog，FZD11，CRJS，Gx，Smoothened Receptor，Smoothened， Seven Transmembrane Spanning Receptor，Smoothened (Drosophila) Homolog
Molekülhintergrund
The protein encoded by this gene is a G protein-coupled receptor that interacts with the patched protein, a receptor for hedgehog proteins. The encoded protein tranduces signals to other proteins after activation by a hedgehog protein/patched protein complex.
SMO Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Patidegib | SGT-610; BBP-009; FIN-5; IPI-926 | Phase 3 Clinical | Infinity Pharmaceuticals Inc | Adenocarcinoma; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Chondrosarcoma; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms; Primary Myelofibrosis | Details |
| Taladegib | ENV-IPF-101; ENV-ONC-101; LY-2940680; ENV-101; RXDX-109 | Phase 2 Clinical | Eli Lilly And Company | Breast Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Medulloblastoma; Neoplasm Metastasis; Neoplasms; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Solid tumours | Details |
| GT-1708F | GT-1708F; GT-1708; GT1708F | Phase 2 Clinical | Suzhou Koshine Biomedica Inc | Hematologic Neoplasms; Idiopathic Pulmonary Fibrosis; Solid tumours | Details |
| Cipromedegib | SHR-1539 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Solid tumours | Details |
| ZSP-1602 | ZSP-1602 | Phase 1 Clinical | Guangdong Zhongsheng Pharmaceutical Co Ltd | Carcinoma; Carcinoma, Basal Cell; Carcinoma, Neuroendocrine; Esophageal Neoplasms; Glioblastoma; Glioma; Medulloblastoma; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Sonidegib Diphosphate | LDE-225; NVP-LDE-225 | Approved | Novartis Pharma Ag | Odomzo, 奥昔朵 | United States | Carcinoma, Basal Cell | Sun Pharmaceutical Industries Ltd | 2015-07-24 | Astrocytoma; Basal Cell Nevus Syndrome; Blood Coagulation Disorders; Blood Platelet Disorders; Bone Marrow Diseases; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Graft vs Host Disease; Hematologic Diseases; Hematologic Neoplasms; Hemorrhagic Disorders; Hepatic Insufficiency; Hepatoblastoma; HR-positive breast cancer; Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Liver Cirrhosis; Liver Dysfunction; Lung Neoplasms; Medulloblastoma; Metastatic breast cancer; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Neuroblastoma; Ovarian Neoplasms; Pancreatic Neoplasms; Polycythemia Vera; Primary Myelofibrosis; Prostatic Neoplasms; Rhabdomyosarcoma; Skin Neoplasms; Solid tumours; Stomach Neoplasms; Thrombocythemia, Essential; Thrombocytosis; | Details |
| Glasdegib | PF-04; PF-4449913; PF-04449913 | Approved | Pfizer Inc | Daurismo | United States | Leukemia, Myeloid, Acute | Pfizer Inc | 2018-11-21 | Fasciitis; Graft vs Host Disease; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Primary Myelofibrosis; Renal Insufficiency; Solid tumours | Details |
| Vismodegib | R-3616; RG-3616; GDC-0449 | Approved | F. Hoffmann-La Roche Ltd, Genentech Inc | Erivedge | United States | Carcinoma, Basal Cell | Genentech Inc | 2012-01-30 | Adenocarcinoma; Basal Cell Nevus Syndrome; Brain Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Central Nervous System Lymphoma; Chondrosarcoma; Chondrosarcoma, Clear Cell; Chondrosarcoma, Extraskeletal Myxoid; Chondrosarcoma, Mesenchymal; Colorectal Neoplasms; Dermatofibrosarcoma; Desmoplastic Small Round Cell Tumor; Esophageal Neoplasms; Fibrosarcoma; Gastrointestinal Stromal Tumors; Glioblastoma; Gliosarcoma; Graft vs Host Disease; Hemangioendothelioma, Epithelioid; Hemangiosarcoma; Hematologic Neoplasms; Idiopathic Pulmonary Fibrosis; Leiomyosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Medulloblastoma; Mesenchymoma; Multiple Myeloma; Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Neurofibrosarcoma; Odontogenic Cyst, Calcifying; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Sarcoma, Alveolar Soft Part | Details |